TG Therapeutics (TGTX) Receives Analyst Rating

TG Therapeutics (TGTX) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 7 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

TG Therapeutics (TGTX) : 7 Wall Street analysts covering TG Therapeutics (TGTX) believe that the average level the stock could reach for the short term is $23.71. The maximum price target given is $33 and the minimum target for short term is around $15, hence the standard deviation is calculated at $6.78.


TG Therapeutics (NASDAQ:TGTX): After opening at $7.02, the stock dipped to an intraday low of $6.92 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $7.41 and the buying power remained strong till the end. The stock closed at $7.28 for the day, a gain of 4.00% for the day session. The total traded volume was 470,596. The stocks close on the previous trading day was $7.

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. As of December 31, 2014, TG had two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. As of December 31, 2014, both TG-1101 and TGR-1202 were in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop inhibitors of IRAK4 (interleukin-1 receptor-associated kinase 4), as well as an antibody research program to develop anti-PD-L1 and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies, which were in pre-clinical development as of December 31, 2014.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *